Download PDF
Planta Med 2005; 71(2): 191-193
DOI: 10.1055/s-2005-837791
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Combretastatins D-3 and D-4, New Macrocyclic Lactones from Getonia floribunda

Namphung Vongvanich1 , Prasat Kittakoop2 , Panarat Charoenchai2 , Sutichai Intamas2 , Kannawat Danwisetkanjana2 , Yodhathai Thebtaranonth2
  • 1Department of Chemistry, Faculty of Science, Mahidol University, Bangkok, Thailand
  • 2National Center for Genetic Engineering and Biotechnology (BIOTEC), NSTDA, Klong Luang, Pathumthani, Thailand
Further Information

Publication History

Received: May 20, 2004

Accepted: September 5, 2004

Publication Date:
24 February 2005 (online)

    Permissions and Reprints

Abstract

Chemical investigation of biologically active compounds of Getonia floribunda led to the isolation of two new macrocyclic lactones, combretastatins D-3 (1) and D-4 (2). The structures of these compounds were confirmed by spectroscopic analyses. Combretastatin D-3 (1) exhibited cytotoxicity towards the small-cell lung cancer cell line (NCI-H187, IC50 = 13.0 ± 0.2 μg/mL) but was inactive against KB, BC-1, and Vero cell lines. Combretastatin D-3 (1) showed weak antitubercular activity with a minimum inhibitory concentration (MIC) of 100.0 μg/mL, and was inactive towards the malarial parasite. Combretastatin D-4 (2) was inactive in all antitubercular, antiplasmodial, and cytotoxic assays.

References

  • 1 Pettit G R, Cragg G M, Herald D L, Schmidt J M, Lohavanijaya P. Isolation and structure of combretastatin.  Can J Chem. 1982;  60 1374-6
    CrossrefPubMedGoogle Scholar
  • 2 Pettit G R, Cragg G M, Singh S B. Antineoplastic agents, 122. Constituents of Combretum caffrum .  J Nat Prod. 1987;  50 386-91
    CrossrefPubMedGoogle Scholar
  • 3 Pettit G R, Singh S B, Niven M L, Hamel E, Schmidt J M. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum .  J Nat Prod. 1987;  50 119-31
    CrossrefPubMedGoogle Scholar
  • 4 Pettit G R, Singh S B. Isolation, structure, and synthesis of combretastatins A-2, A-3, and B-2.  Can J Chem. 1987;  65 2390-6
    CrossrefPubMedGoogle Scholar
  • 5 Dark G G, Hill S A, Prise V E, Tozer G M, Pettit G R, Chaplin D J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.  Cancer Res. 1997;  57 1829-34
    PubMedGoogle Scholar
  • 6 Pettit G R, Singh S B, Niven M L. Isolation and structure of combretastatin D-1: A cell growth inhibitory macrocyclic lactone from Combretum caffrum .  J Am Chem Soc. 1988;  110 8539-40
    CrossrefPubMedGoogle Scholar
  • 7 Singh S B, Pettit G R. Antineoplastic agents. 206. Structure of the cytostatic macrocyclic lactone combretastatin D-2.  J Org Chem. 1990;  55 2797-800
    CrossrefPubMedGoogle Scholar
  • 8 Nabha S M, Mohammad R M, Dandashi M H, Coupaye-Gerard B, Aboukameel A, Pettit G R, Al-Katib A M. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly (ADP-ribose) polymerase cleavage.  Clin Cancer Res. 2002;  8 2735-41
    PubMedGoogle Scholar
  • 9 Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis.  Br J Cancer. 2003;  89 1334-44
    CrossrefPubMedGoogle Scholar
  • 10 Nam N H. Combretastatin A-4 analogues as antimitotic antitumor agents.  Curr Med Chem. 2003;  10 1697-722
    CrossrefPubMedGoogle Scholar
  • 11 Bayes M, Rabasseda X, Prous J R. Gateways to clinical trials.  Methods Find Exp Clin Pharmacol. 2003;  25 145-68
    PubMedGoogle Scholar
  • 12 Cirla A, Mann J. Combretastatins: from natural products to drug discovery.  Nat Prod Rep. 2003;  20 558-64
    CrossrefPubMedGoogle Scholar
  • 13 Couladouros E A, Li T, Moutsos V I, Pitsinos E N, Soufli I C. Stabilization of microtubules by combretastatin D derivatives.  Bioorg Med Chem Lett. 1999;  9 2927-8
    CrossrefPubMedGoogle Scholar
  • 14 Rychnovsky S D, Hwang K. Synthesis of (+/-)-combretastatin D-1 and combretastatin D-2.  J Org Chem. 1994;  59 5414-8
    PubMedGoogle Scholar
  • 15 Deshpande V H, Gokhale N . Synthesis of combretastatin D-2+.  Tetrahedron Lett. 1992;  33 4213-6
    CrossrefPubMedGoogle Scholar
  • 16 Boger D L, Sakya S M, Yohannes D. Total synthesis of combretastatin D-2: intramolecular Ullmann macrocyclization reaction.  J Org Chem. 1991;  56 4204-7
    Google Scholar
  • 17 Collins L, Franzblau S G. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium .  Antimicrob Agents and Chemother. 1997;  41 1004-9
    PubMedGoogle Scholar
  • 18 Skehan P, Storend R, Scudiero D, Monks A, McMahon J, Visrica D, Warren J T, Bokesch H, Kenny S, Boyd M R. New colorimetric cytotoxicity assay for anticancer drug screening.  J Natl Cancer Inst. 1990;  82 1107-12
    CrossrefPubMedGoogle Scholar
  • 19 Trager W, Jensen J B. Human malaria parasites in continuous culture.  Science. 1976;  193 673-5
    CrossrefPubMedGoogle Scholar
  • 20 Desjardins R E, Canfield C J, Haynes J D, Chulay J D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique.  Antimicrob Agents and Chemother. 1979;  16 710-8
    PubMedGoogle Scholar

Dr. Prasat Kittakoop

National Center for Genetic Engineering and Biotechnology

NSTDA

Thailand Science Park

113 Paholyothin Road

Klong 1

Klong Luang

Pathumthani 12120

Thailand

Phone: +662-564-6700 ext. 3560

Fax: +662-564-6707

Email: prasat@biotec.or.th

      >